CAS 229644-17-1
:S-[[(3S,6S)-3,4,5-trihydroxy-6-(4-methyl-2-oxo-chromen-7-yl)oxy-tetrahydropyran-2-yl]methyl] hexadecanethioate
- Lower prices
- Higher prices
- Lower purities
- Higher purities
- Faster estimated delivery
Mu-6S-Palm-β-Glc
CAS:Mu-6S-Palm-β-Glc is a fluorogenic substrate for PPT1. It monitors enzyme activity via fluorescence and is used in the research of infantile neuronal ceroid lipofuscinosis (INCL) diagnostics and lysosomal storage disease therapies.Formula:C32H48O8SColor and Shape:White SolidMolecular weight:592.784-Methylumbelliferyl 6-Thio-palmitate-Beta-D-glucopyranoside
CAS:Controlled ProductApplications A fluorogenic substrate for the assay of Palmitoyl-Protein Thioesterase, used in the diagnosis of infantile neuronal ceroid lipofuscinosis (INCL).
References Goebel, H., et al.: J. Child Neurol., 10, 424 (1995), Verkruyse, L., et al.: J. Biol. Chem., 271, 15831 (1996), Sleat, D., et al.: Science, 277, 1802 (1997), Cho, S., et aL.: J. Neurochem., 71, 323 (1998),Formula:C32H48O8SColor and Shape:NeatMolecular weight:592.784-Methylumbelliferyl 6-thio-palmitate-b-D-glucopyranoside - Moscerdam™ biochemical purity
CAS:4-Methylumbelliferyl 6-thio-palmitate-b-D-glucopyranoside (Mu-6S-Palm-β-Glc) is a fluorogenic substrate of palmitoyl-protein thioesterase 1 (PPT1), used in the diagnosis of infantile neuronal ceroid lipofuscinosis (INCL). INCL, also known as infantile CLN1 disease, is a rapidly progressing lysosomal storage disorder (LSD), caused by a deficiency of PPT1. Mu-6S-Palm-β-Glc is also used as the substrate in the PPT assay to investigate the retention of lysosomal enzyme activity of bi-functional IgG-PPT1 fusion protein in the delivery across blood-brain barrier.
Formula:C32H48O8SPurity:Min. 95%Color and Shape:White PowderMolecular weight:592.78 g/molS-(((2S,3S,4S,5R,6S)-3,4,5-Trihydroxy-6-((4-methyl-2-oxo-2H-chromen-7-yl)oxy)tetrahydro-2H-pyran-2-yl)methyl) hexadecanethioate
CAS:Formula:C32H48O8SPurity:98.00%Color and Shape:SolidMolecular weight:592.7837






